Showing results (41-50 of 97) with videos related to
Sort By:
Pageof 10
The Lancet. Haematology|September 3, 2017
Investigation of a gene signature to predict response to immunomodulatory derivatives for patients with multiple myeloma: an exploratory, retrospective study using microarray datasets from prospective clinical trialsManisha Bhutani, Qing Zhang, Reed Friend, et al.American Journal of Hematology|September 24, 2021
A phase I/II study of ixazomib, pomalidomide, and dexamethasone for lenalidomide and proteasome inhibitor refractory multiple myeloma (Alliance A061202)Peter M Voorhees, Vera J Suman, Sascha A Tuchman, et al.Journal of the Advanced Practitioner in Oncology|October 9, 2023
Patient-Reported Outcomes With Belantamab Mafodotin Treatment in Patients With Triple-Class Refractory Multiple MyelomaRakesh Popat, Sagar Lonial, Peter M Voorhees, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 18, 2020
Low-dose versus High-dose Carfilzomib with Dexamethasone (S1304) in Patients with Relapsed-Refractory Multiple MyelomaSikander Ailawadhi, Rachael Sexton, Suzanne Lentzsch, et al.Blood|June 27, 2007
Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myelomaDeborah J Kuhn, Qing Chen, Peter M Voorhees, et al.British Journal of Haematology|January 19, 2011
Blockade of interleukin-6 signalling with siltuximab enhances melphalan cytotoxicity in preclinical models of multiple myelomaSally A Hunsucker, Valeria Magarotto, Deborah J Kuhn, et al.Clinical Lymphoma, Myeloma & Leukemia|May 8, 2025
Stem Cell Mobilization Yields with Daratumumab (Dara) and Lenalidomide (Len)-Containing Quadruplet Induction Therapy in Patients with Newly Diagnosed Multiple Myeloma (NDMM): A Real-World Experience at 2 InstitutesCindy Varga, Myra Robinson, Vikas Gupta, et al.Cancer Treatment and Research Communications|March 19, 2026
Systematic literature review of secondary primary malignancies related to a CAR-T treatment in patients with multiple myeloma, lymphoma or leukemiaMounzer E Agha, Sarah McGregor, Kevin C De Braganca, et al.European Journal of Haematology|June 13, 2023
Bone marrow Ki-67 index is of prognostic value in newly diagnosed multiple myelomaShebli Atrash, Myra Robinson, Alankrita Taneja, et al.Ejhaem|July 18, 2022
Ex vivo efficacy of BCMA-bispecific antibody TNB-383B in relapsed/refractory multiple myelomaDavid M Foureau, Manisha Bhutani, Myra Robinson, et al.Pageof 10